A breath test for malignant mesothelioma using an electronic nose

Our study has demonstrated that carbon polymer array electronic nose breath profiling allows accurate discrimination between patients with MM, healthy control subjects and subjects with benign asbestos-related diseases

Eleanor A. Chapman

2011

Scholarcy highlights

  • Malignant mesothelioma is a rare tumour which is difficult to diagnose in its early stages
  • FEV1, FVC and FEV1/FVC ratio were significantly reduced in subjects with benign asbestos-related diseases compared with healthy control subjects
  • Our study has demonstrated that carbon polymer array electronic nose breath profiling allows accurate discrimination between patients with MM, healthy control subjects and subjects with benign ARDs
  • This is the second published report of the use of electronic nose breath profiling in MM and substantiates the promise of this technique as a simple, easy way for detecting malignancy which has previously been reported for lung cancer
  • A study by DRAGONIERI et al published very recently, while our paper was under review, reports high levels of discrimination between patients with MM and those with long-term asbestos exposure using an electronic nose system, with results almost identical to those of our study
  • Smell prints from 10 new MM patients were distinguished from control subjects with an accuracy of 95%
  • This work exemplifies the novel use of this technology for differentiating individuals with asbestos exposure and benign conditions from those with malignant disease
  • The carbon polymer array electronic nose distinguished accurately between benign and malignant asbestos-related diseases, implying that the breath profile of volatile organic compounds in MM is very different

Need more features? Save interactive summary cards to your Scholarcy Library.